2. Search Result
Search Result
Results for "

ferrets

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-135853
    Molnupiravir
    70+ Cited Publications

    EIDD-2801; MK-4482

    		 SARS-CoV Influenza Virus Infection
    Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza .
    Molnupiravir
  • HY-14751
    Rolapitant

    SCH619734

    		 Neurokinin Receptor Neurological Disease
    Rolapitant (SCH619734) is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant does not interact with CYP3A4. Rolapitant shows potent anti-emetic activity in a ferret emesis model .
    Rolapitant
  • HY-145586
    Onradivir

    ZSP1273

    		 Influenza Virus DNA/RNA Synthesis Infection
    Onradivir (ZSP1273) is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir can be used for the research of influenza A virus infection .
    Onradivir
  • HY-16436
    Rolapitant hydrochloride hydrate

    SCH619734 hydrochloride hydrate

    		 Neurokinin Receptor Neurological Disease Cancer
    Rolapitant hydrochloride hydrate (SCH619734 hydrochloride hydrate) is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant hydrochloride hydrate does not interact with CYP3A4. Rolapitant hydrochloride hydrate shows potent anti-emetic activity in a ferret emesis model .
    Rolapitant hydrochloride hydrate
  • HY-145119
    GS-621763

    		SARS-CoV Infection
    GS-621763 is an orally available precursor to GS-441524 that exhibits anti-SARS-CoV-2 viral activity in mice. GS-621763 reduces viral load to undetectable levels in ferrets infected with SARS-CoV-2 .
    GS-621763
  • HY-116649
    CB1 antagonist 2

    AM4113

    		 Cannabinoid Receptor Neurological Disease Metabolic Disease
    CB1 antagonist 2 (AM4113) is an orally active cannabinoid receptor type 1 (CB1R) antagonist. CB1 antagonist 2 suppresses appetite, reduces body weight, and blocks addictive behaviors such as heroin addiction, without causing adverse effects like nausea and depression that are associated with traditional CB1 inverse agonists. CB1 antagonist 2 can be used in studies related to obesity and opioid addiction .
    CB1 antagonist 2
  • HY-103333
    Arvanil

    N-Vanillylarachidonamide

    		 TRP Channel Cannabinoid Receptor CD74 Akt Orexin Receptor (OX Receptor) Neurological Disease Inflammation/Immunology
    Arvanil (N-Vanillylarachidonamide) is a mixed agonist of CB1 and TRPV1 receptors. Arvanil downregulates CD25, HLA-DR, CD134/OX40, blocks G1/S phase transition, and induces phosphorylation of Akt. Arvanil does not induce apoptosis in cells. Arvanil inhibits lymphocyte activation and ameliorates autoimmune encephalomyelitis. Arvanil can be used in research related to Huntington's disease, vomiting, and multiple sclerosis .
    Arvanil
  • HY-103409
    ABT-724 trihydrochloride

    		Dopamine Receptor Neurological Disease
    ABT-724 trihydrochloride is a potent and highly selective dopamine D4 receptor agonist with an EC50 of 12.4 nM for human dopamine D4 receptor. ABT-724 trihydrochloride is a potent partial agonist at the rat D4 (EC50 of 14.3 nM) and the ferret D4 receptor (EC50 of 23.2 nM), and has no effect on dopamine D1, D2, D3, or D5 receptors. ABT-724 trihydrochloride could be useful for the treatment of erectile dysfunction and has favorable side-effect profile .
    ABT-724 trihydrochloride
  • HY-178269
    SCH-720881

    		Drug Metabolite Neurokinin Receptor Neurological Disease
    SCH-720881 is the active metabolite of Rolapitant (HY-14751). Rolapitant (SCH619734) is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant does not interact with CYP3A4. Rolapitant shows potent anti-emetic activity in a ferret emesis model .
    SCH-720881
  • HY-14330
    ABT-724

    		Dopamine Receptor Neurological Disease
    ABT-724, a chemical probe, is a potent and highly selective dopamine D4 receptor agonist with an EC50 of 12.4 nM for human dopamine D4 receptor. ABT-724 is a potent partial agonist at the rat D4 (EC50 of 14.3 nM) and the ferret D4 receptor (EC50 of 23.2 nM). ABT-724 has no effect on dopamine D1, D2, D3, or D5 receptors. ABT-724 could be useful for the treatment of erectile dysfunction and has favorable side-effect profile .
    ABT-724
  • HY-119095
    L-741671

    		Neurokinin Receptor Neurological Disease Endocrinology
    L-741671 is a selective and brain-permeable antagonist of neurokininl (hNKI) receptor, with Kis of 64 nM, 0.03 nM and 0.7 nM in rat, human and ferret, respectively .
    L-741671
  • HY-19483
    ABT-670

    		Dopamine Receptor Neurological Disease
    ABT-670 is a selective, oral bioavailable agonist of dopamine D4 receptor, with EC50 of 89 nM, 160 nM, and 93 nM for human D4, ferret D4, and rat D4, respectively.
    ABT-670
  • HY-171948
    FO-35

    		Liposome Cancer
    FO-35 is an ionizable lipid that can be used to synthesize lipid nanoparticles (LNPs). FO-35 can be used to delivery mRNA to mouse muscle and nasal mucosa as well as ferret lungs .
    FO-35
  • HY-135853R
    Molnupiravir (Standard)

    EIDD-2801 (Standard); MK-4482 (Standard)

    		 Reference Standards SARS-CoV Influenza Virus Infection
    Molnupiravir (Standard) is the analytical standard of Molnupiravir. This product is intended for research and analytical applications. Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza .
    Molnupiravir (Standard)
  • HY-145586A
    Onradivir monohydrate

    ZSP1273 monohydrate

    		 Influenza Virus DNA/RNA Synthesis Infection
    Onradivir (ZSP1273) monohydrate is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir monohydrate inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir monohydrate maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir monohydrate can be used for the research of influenza A virus infection .
    Onradivir monohydrate
  • HY-14751A
    Rolapitant hydrochloride

    SCH619734 hydrochloride

    		 Neurokinin Receptor Neurological Disease Cancer
    Rolapitant (SCH619734) hydrochloride is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant hydrochloride does not interact with CYP3A4. Rolapitant hydrochloride shows potent anti-emetic activity in a ferret emesis model .
    Rolapitant hydrochloride
  • HY-14751R
    Rolapitant (Standard)

    SCH619734 (Standard)

    		 Reference Standards Neurokinin Receptor Neurological Disease Cancer
    Rolapitant (Standard) is the analytical standard of Rolapitant. This product is intended for research and analytical applications. Rolapitant (SCH619734) is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant does not interact with CYP3A4. Rolapitant shows potent anti-emetic activity in a ferret emesis model .
    Rolapitant (Standard)
  • HY-69317
    RS14203

    PMNPQ

    		 Phosphodiesterase (PDE) Others
    RS14203 is an orally active type IV cyclic nucleotide phosphodiesterase (PDE IV) inhibitor which can induce emesis .
    RS14203
  • HY-176512
    FO-32

    		Liposome Cancer
    FO-32 is an ionizable cationic lipid with a pKa of 6.46 and can be used to generate lipid nanoparticles (LNPs) to deliver mRNA in vivo. FO-32 can efficiently deliver mRNA to ferret lungs. FO-32 can be studied in research on optimizing drug delivery .
    FO-32
  • HY-10049
    CP 122721

    		Neurokinin Receptor Neurological Disease Inflammation/Immunology
    CP 122721 is an orally active NK1 receptor antagonist. CP 122721 attenuates cisplatin-induced vomiting in ferrets (ID50: 0.08 mg/kg). CP 122721 inhibits kainate (KA)-induced seizure activity and CA1 neuronal cell death in rats. CP 122721 is useful in the study of depression, asthma, and irritable bowel syndrome (IBS) .
    CP 122721
  • HY-106982
    Ezlopitant

    CJ-11,974

    		 Neurokinin Receptor Neurological Disease Metabolic Disease
    Ezlopitant (CJ-11,974) is a selective, non-peptidic neurokinin-1 (NK-1)-receptor antagonist. Ezlopitant inhibits both acute and delayed emetic reactions induced by Cisplatin (HY-17394) in ferrets via acting on NK1 receptors in the central nervous system. Ezlopitant has the potential for pain, chemotherapy-induced emesis and irritable bowel syndrome research .
    Ezlopitant
  • HY-180882
    GHP-88310

    EIDD-3608

    		 DNA/RNA Synthesis Infection
    GHP-88310 (EIDD-3608) is a potent, orally active orthoparamyxovirus polymerases inhibitor. GHP-88310 exhibits potent activity against HPIV3 and related respiroviruses, measles virus (MeV) and related morbilliviruses. GHP-88310 exhibits efficacy in both canine distemper virus (CDV) ferret models and HPIV3 cotton rat models. GHP-88310 can be used for orthoparamyxovirus disease research .
    GHP-88310
  • HY-182701
    5-HT3 antagonist-7

    		5-HT Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology
    5-HT3 antagonist-7 (Compound 7e) is a competitive and selective 5-HT3 receptor antagonist. 5-HT3 antagonist-7 inhibits 5-HT-induced contractions in guinea pig ileum and guinea pig thoracic aorta. 5-HT3 antagonist-7 prevents 2-methyl-5-HT-induced vomiting episodes in ferrets .
    5-HT3 antagonist-7
  • HY-103409R
    ABT-724 trihydrochloride (Standard)

    		Reference Standards Dopamine Receptor Neurological Disease
    ABT-724 trihydrochloride (Standard) is the analytical standard of ABT-724 trihydrochloride (HY-103409). This product is intended for research and analytical applications. ABT-724 trihydrochloride is a potent and highly selective dopamine D4 receptor agonist with an EC50 of 12.4 nM for human dopamine D4 receptor. ABT-724 trihydrochloride is a potent partial agonist at the rat D4 (EC50 of 14.3 nM) and the ferret D4 receptor (EC50 of 23.2 nM), and has no effect on dopamine D1, D2, D3, or D5 receptors. ABT-724 trihydrochloride could be useful for the treatment of erectile dysfunction and has favorable side-effect profile .
    ABT-724 trihydrochloride (Standard)
  • HY-183136
    Batanopride

    BMY 25801

    		 5-HT Receptor Cancer
    Batanopride (BMY 25801) is a selective 5-HT3 receptor antagonist. Batanopride inhibits chemotherapy-induced emesis, and prevents Cisplatin (HY-17394)-, Cyclophosphamide (HY-17420)-, Doxorubicin (HY-15142A)-, and total body irradiation-induced emesis .
    Batanopride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: